drugset / Trial / NCT04135508

A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira

NCT04135508

Phase 3 Completed 554 enrolled Bio-Thera Solutions
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira

Timeline

Start
2016-12-13
Primary completion
2018-03-22
Completion
2018-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject BAT1406 Unknown 40 mg Subcutaneous